Home / Expertise / Intellectual Property
padlock hanging from turquoise painted wooden doors

Intellectual Property

Italy

CMS Adonnino Ascoli & Cavasola Scamoni prides itself to be a true partner to growing companies and enterprises, with the aim to most effectively leverage their intellectual assets. The strength of our team relies in the capacity of executing strategic intellectual property litigation, enforcing IP rights and defending against claims of infringement. The team can draw upon a strong team of professionals which have the experience and resources to provide our clients with the best available representation in intellectual property cases. We regularly litigate intellectual property issues in general including: patent, copyright, trade secret, and trademark litigation. Our intellectual property team aims to help our clients establish a competitive position for the future, and ultimately, provide them with value for their intellectual assets.

Read more Read less

Feed

Show only
CMS Ex­pert Guide to Post BEPS In­tel­lec­tu­al Prop­erty...
15 Jan 20
Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
04/07/2017
In­ven­tions and self-em­ploy­ment
CMS News­let­ter Italia | 04 luglio 2017
20 Dec 19
‘Dar­unavir’ CJEU re­fer­ral with­drawn - Art­icle 3(a) of the SPC Reg­u­la­tion
At the end of Septem­ber, we re­por­ted here on the pub­lic­a­tion of AG Hogan’s Opin­ion on the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from...
15/02/2013
Get­ting the Deal Through - Li­cen­cing 2013
17 Dec 19
The rise of pat­ent wars in Europe’s gene ther­apy space
The gene ther­apy in­dustry is in an ex­cit­ing phase of growth, un­der­go­ing sig­ni­fic­ant M&A activ­ity, product sales and new mar­ket­ing au­thor­isa­tions that are be­ing is­sued with in­creas­ing reg­u­lar­ity glob­ally....
16/03/2012
Get­ting the Deal Through - Li­cens­ing 2012
21 Oct 19
AG Opin­ion in SkyKick: Guid­ance on the re­quire­ment for clar­ity and...
Sum­mary The eagerly awaited Ad­voc­ate Gen­er­al Opin­ion in the SkyKick case (C-317/18) was pub­lished last week. The Opin­ion from AG Tanchev relates to ques­tions re­ferred to the CJEU by the UK High Court...
13/04/2011
CMS AACS Alert 13/04/2011
18 Oct 19
Re­vised Rules of Pro­ced­ure of the European Pat­ent Of­fice Boards of...
The Rules of Pro­ced­ure of the Boards of Ap­peal are the rules that gov­ern the way ap­peals are con­duc­ted at the European Pat­ent Of­fice (EPO). The EPO has re­cently ap­proved changes to these rules, which...
08 Oct 19
EU copy­right in designs - CJEU rule in Cofemel that ‘ori­gin­al­ity’...
On 12 Septem­ber 2019, the Court of Justice of the European Uni­on (‘CJEU’) de­livered its judg­ment in the case of Cofemel, C-683/17 con­cern­ing copy­right in designs. In a rul­ing that will be wel­comed...
13 Sep 19
SPC Double Whammy - In­ter­pret­ing Art­icle 3(a) of the SPC Reg­u­la­tion
Sum­mary At the end of June, the CJEU heard the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from the Eng­lish Court of Ap­peal for Searle’s...